newsfilter
← Latest News
Business Wire·

Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution

Cyteir Therapeutics, Inc. ("Cyteir" or the "Company") (NASDAQ:CYT) today announced that it is discontinuing all development of CYT-0851, its investigational monocarboxylate transporter inhibitor, and that Cyteir's Board